SAILOR (Safety Assessment of Intravitreal Lucentis fOR AMD) Study

Who is the sponsor?
Genentech, Inc.

Who are the patients?
Male or female over the age of fifty years with AMD The participating doctor will evaluate you to determine your eligibility into the study in accordance with the Study Eligibility and Exclusion Criteria.

How long are the eligible patients enrollment?
One year.

When did participation agreement start at our site?
Dec 2005

What is the enrollment goal for the sponsor?

Is the enrollment still open?
No. This study is closed.

What is this study investigating?
This is a Phase IIIb clinical study of LucentisTM (ranibizumab, rhuFAb V2) for patients with all subtypes of new or recurrent active subfoveal wet AMD. The study is designed to evaluate the safety of two different doses (0.3 mg and 0.5 mg) of Lucentis administered once a month for three months and thereafter as needed based on re-treatment criteria.

How is the treatment administered?
Intravitreal injections